Candesartan and cilnidipine (DrugBank: Cilnidipine, Candesartan)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 67 | 多発性嚢胞腎 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00541853 (ClinicalTrials.gov) | December 2007 | 9/10/2007 | CCB Safety Study in Treatment of Hypertension of ADPKD | Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients | Kidney, Polycystic, Autosomal Dominant | Drug: Candesartan;Drug: Candesartan and Cilnidipine;Drug: Candesartan plus non-CCB agents | Kyorin University | Ministry of Health, Labour and Welfare, Japan | Not yet recruiting | 20 Years | 60 Years | Both | 150 | Phase 4 | Japan |